Patents by Inventor Nicolas Desroy

Nicolas Desroy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210238159
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: April 15, 2021
    Publication date: August 5, 2021
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Patent number: 11072611
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R8, W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: July 27, 2021
    Assignee: GALAPAGOS NV
    Inventors: Nicolas Desroy, Bertrand Heckmann, Reginald Christophe Xavier Brys, Agnès Marie Joncour, Christophe Peixoto, Xavier Marie Bock
  • Patent number: 10988454
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: April 27, 2021
    Assignees: AbbVie Overseas S.à.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Patent number: 10981890
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: April 20, 2021
    Assignees: AbbVie Overseas S.à.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Publication number: 20210101903
    Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, X, Y1, Y2, Y3, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of TNF?, interferons, IL-6, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Application
    Filed: November 26, 2018
    Publication date: April 8, 2021
    Inventors: Luke Jonathan ALVEY, Denis Maurice ANNOOT, Florence Marie-Emilie BONNATERRE, Denis BUCHER, Béranger DUTHION, Hélène Marie JARY, Christophe PEIXOTO, Taoues TEMAL-LAIB, Amynata TIRERA, Nicolas DESROY
  • Patent number: 10844042
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: November 24, 2020
    Assignees: AbbVie Overseas S.à.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Patent number: 10844041
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: November 24, 2020
    Assignees: AbbVie Overseas S.à.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Patent number: 10829473
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: November 10, 2020
    Assignees: AbbVie Overseas S.à.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Publication number: 20200277275
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Publication number: 20200277273
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Publication number: 20200277274
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Publication number: 20200277276
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Publication number: 20200239466
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R8, W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Application
    Filed: November 13, 2019
    Publication date: July 30, 2020
    Applicant: Galapagos NV
    Inventors: Nicolas DESROY, Bertrand HECKMANN, Reginald Christophe Xavier BRYS, Agnès Marie JONCOUR, Christophe PEIXOTO, Xavier Marie BOCK
  • Patent number: 10647717
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: May 12, 2020
    Assignees: AbbVie S.á.r.l., Galapagos NV
    Inventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Matthieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Emiel Van der Plas, Xueqing Wang, Ann de Blieck
  • Patent number: 10526329
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R7, R8, W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: January 7, 2020
    Assignee: GALAPAGOS NV
    Inventors: Nicolas Desroy, Bertrand Heckmann, Reginald Christophe Xavier Brys, Agnès Marie Joncour, Christophe Peixoto, Xavier Marie Bock
  • Publication number: 20190330207
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: June 18, 2019
    Publication date: October 31, 2019
    Inventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Matthieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Emiel Van der Plas, Xueqing Wang, Ann de Blieck
  • Publication number: 20190315687
    Abstract: The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: June 14, 2019
    Publication date: October 17, 2019
    Inventors: Robert J. Altenbach, Andrew Bogdan, Nicolas Desroy, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Marc J. Scanio, Xenia B. Searle, Xueqing Wang, Ming C. Yeung, Gang Zhao
  • Patent number: 10428017
    Abstract: The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: October 1, 2019
    Assignees: AbbVie S.á.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Nicolas Desroy, Gregory A. Gfesser, Stephen N. Greszler, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Nuria Merayo Merayo, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung, Gang Zhao
  • Patent number: 10399940
    Abstract: The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: September 3, 2019
    Assignees: AbbVie S.á.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Nicolas Desroy, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Marc J. Scanio, Xenia Searle, Xueqing Wang, Ming C. Yeung, Gang Zhao
  • Publication number: 20190202823
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: March 6, 2019
    Publication date: July 4, 2019
    Inventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Matthieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Emiel Van der Plas, Xueqing Wang, Ann de Blieck